Table 7 The inflammatory signaling pathways and related gene transcripts affected by daily injection of HPG solution compared to Control
Signaling pathways (p value) | Up regulated genes | Down regulated genes |
|---|---|---|
B cell development (0.0240) | – | CD80, HLA-DRA, HLA-DQB1 |
Complement (0.3006, NS) | CFD | – |
Cross talk between DCs and NK cells (0.0759, NS) | – | CD80, MICB, HLADRA, ACTC1 |
Granulocyte adhesion and diapedesis (0.0014) | CLDN5, CXCR2, ITGA2, CXCL14, CCL21, CCL11, CXCL6 | CXCL10, IL1RAPL1 |
Agranulocyte adhesion and diapedesis (0.0071) | CLDN5, CXCR2, ITGA2, CXCL14, CCL21, CCL11, CXCL6 | CXCL10, ACTC1 |
ICOS/ICOSL signaling in Th cells (0.0063) | CD80, GRAP2, HLA-DRA, PIK3C2G, ICOSLG/LOC102723996 | CD80, GRAP2, HLA-DRA, HLA-DQB1 |
Antigen presentation pathway (0.4875, NS) | – | HLA-DRA |
Nur 77 signaling in T cells (0.0891, NS) | – | CD80, HLA-DRA, HLA-DQB1 |
Acute phase response signaling (0.0813, NS) | PIK3R3, VWF, KRAS, CRABP1 | – |
CD28 signaling in Th cells (0.0302) | PIK3R3, PIK3C2G | CD80, GRAP2, HLA-DRA, HLA-DQB1 |
IL-17 signaling in fibroblast (0.4677, NS) | – | CEBPD |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.5395, NS) | – | CXCL10 |
IL-10 signaling (NC) | – | – |
Differential regulation of cytokine production in MΦ and Th cells (NC) | – | – |
Inhibition of matrix metalloproteinase (NC) | – | – |
TREM1 signaling (NC) | – | – |
IL-6 signaling (0.1923, NS) | PIK3R3, PIK3C2G, KRAS | IL1RAPL1 |
Toll-like receptor signaling (NC) | – | – |
MIF-mediated glucocortical regulation (0.1169, NS) | PLA2G5, PLA2G2A | – |
MIF regulation of innate immunity (0.1660, NS) | PLA2G5, PLA2G2A | – |
HMGB1 signaling (0.4246, NS) | PIK3R3, PIK3C2G, KRAS | – |